Skip to content
Longterm Wiki

CEPI Appoints Aurélia Nguyen as Deputy CEO

web
CEPI·cepi.net/cepi-appoints-aurelia-nguyen-deputy-ceo

Credibility Rating

4/5
High(4)

High quality. Established institution or organization with editorial oversight and accountability.

Rating inherited from publication venue: CEPI

This press release announces leadership changes at CEPI, a global health organization focused on pandemic preparedness. While not directly related to AI safety, CEPI's 100-day vaccine response mission touches on biosecurity and pandemic preparedness, which intersects with existential risk and global catastrophic biological risk concerns relevant to the broader AI safety community.

Metadata

Importance: 8/100press releasenews

Summary

CEPI has appointed Aurélia Nguyen, formerly of Gavi's COVAX Facility, as its new Deputy CEO to support the organization's CEPI 2.0 five-year strategy. The strategy aims to prepare the world to respond to the next Disease X threat within 100 days. Additional executive leadership appointments were also announced, including Kent Kester as Executive Director of Vaccine R&D.

Key Points

  • •Aurélia Nguyen joins CEPI as Deputy CEO from Gavi, where she led the COVAX Facility as Managing Director.
  • •Her role will support CEPI's 2.0 strategy to enable a 100-day response to future pandemic threats (Disease X).
  • •Kent Kester joins as Executive Director of Vaccine R&D, coming from IAVI and previously Sanofi Pasteur and WRAIR.
  • •Organizational restructuring includes new divisions for External/Investor Relations and Access and Business Development.
  • •These changes aim to strengthen CEPI's leadership ahead of what it describes as a critical period in its development.

Cached Content Preview

HTTP 200Fetched May 18, 20265 KB
Facebook LinkedIn X OSLO, 26 Jul – Global health expert Aurélia Nguyen has been appointed Deputy Chief Executive Officer of CEPI, the global organisation working to accelerate the development of vaccines against epidemic and pandemic threats and make them accessible to populations in need.

 Aurélia joins CEPI from Gavi, the Vaccine Alliance – where she held roles including Chief Programme Officer and Managing Director of the Covax Facility. Aurélia has a proven track record in driving the design of vaccine programmes and delivery of new vaccines as well as extensive leadership experience with a particular focus on gender and diversity.

 In her new role as Deputy CEO she will support CEPI CEO Dr Richard Hatchett and the CEPI team in advancing CEPI’s five-year strategy, known as CEPI 2.0 , which will help Prepare, Transform and Connect the world so that it can respond to the next Disease X threat in as little as 100 days.

 Welcoming Aurélia to the new role Dr Richard Hatchett, CEO of CEPI , said: “I am delighted that Aurélia will be joining us as CEPI’s new Deputy CEO. Aurélia has always been an incredible partner to CEPI and has an impressive track record both in leading teams and in delivering ambitious plans to improve access to vaccines. She brings both a wealth of experience from her career in the multilateral and private sectors and fresh thinking to what is going to be a critical role at CEPI”.

 Aurélia Nguyen said: “I have spent many wonderful years at Gavi, and it feels very fitting that my next challenge is with CEPI - an organisation I know well, and which is so well aligned to the work I have done throughout my career of increasing equity through access to life-saving products. It really is a privilege to be joining such a talented and dedicated team at what I believe is a critical time in CEPI’s development, and I am looking forward immensely to getting started. It has been an honour to work at Gavi, and I hope to remain a champion and further Gavi and CEPI’s shared goal to protect people’s health with vaccines in this new role.” 

 Aurélia Nguyen takes over the position from Dr Frederik Kristensen who is now Managing Director of the Regional Vaccine Manufacturing Collaborative (RVMC) . She will assume her role on October 1.

 Today, CEPI also announced further organisational updates to strengthen CEPI’s Executive Leadership Team. 

 On August 6, Kent Kester will join CEPI as Executive Director of Vaccine R&D (VRD), assuming responsibility for CEPI’s scientific programmes to accelerate the development of novel countermeasures and rapid response vaccine platforms against emerging infectious disease threats. He comes to CEPI from IAVI, where he served as the Vice President of Translational Medicine. Previously, he served as Vice President and Head of Translational Science and Biomarkers at Sanofi Pasteur, as Commander at the Walter Reed Army Institute of Research (WRAIR), and as the Associate Dean for Clinical Research at the Uniform

... (truncated, 5 KB total)
Resource ID: 0b6a5a6e82c2ad75 | Stable ID: sid_dFGzwqYgQw